ABS-201 — Interim data
2H 2026
2H 2026: Expected 13-week interim PoC readoutSource filing
ABSI biotech catalysts & pipeline
ABSCI CORP · Data as of 2026-09-08
Upcoming catalysts
ABS-201 — Topline data
Early 2027
Absci anticipates reporting interim proof-of-concept data from this study in the second half of 2026 and full proof-of-concept data in early 2027.Source filing
ABS-201 — Interim data
H2 2027
With the safety, tolerability, and PK data generated in the ongoing HEADLINE trial, Absci anticipates initiation of a Phase 2 clinical trial for endometriosis in the fourth quarter of 2026, with potential proof-of-concept data in the second half of 2027.Source filing